- Home
- WSC vs KRYS Comparison
WSC vs KRYS Comparison
Compare WSC & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSC
- KRYS
- Stock Information
- Founded
- WSC 1944
- KRYS 2015
- Country
- WSC United States
- KRYS United States
- Employees
- WSC N/A
- KRYS N/A
- Industry
- WSC Misc Corporate Leasing Services
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WSC Industrials
- KRYS Health Care
- Exchange
- WSC Nasdaq
- KRYS Nasdaq
- Market Cap
- WSC 5.3B
- KRYS 4.3B
- IPO Year
- WSC N/A
- KRYS 2017
- Fundamental
- Price
- WSC $23.71
- KRYS $150.27
- Analyst Decision
- WSC Buy
- KRYS Strong Buy
- Analyst Count
- WSC 7
- KRYS 10
- Target Price
- WSC $36.00
- KRYS $204.90
- AVG Volume (30 Days)
- WSC 2.1M
- KRYS 258.6K
- Earning Date
- WSC 10-29-2025
- KRYS 11-03-2025
- Dividend Yield
- WSC 1.19%
- KRYS N/A
- EPS Growth
- WSC N/A
- KRYS 36.22
- EPS
- WSC 0.59
- KRYS 4.91
- Revenue
- WSC $2,352,581,000.00
- KRYS $359,205,000.00
- Revenue This Year
- WSC N/A
- KRYS $34.33
- Revenue Next Year
- WSC $3.15
- KRYS $47.84
- P/E Ratio
- WSC $40.27
- KRYS $30.70
- Revenue Growth
- WSC N/A
- KRYS 116.08
- 52 Week Low
- WSC $21.91
- KRYS $122.80
- 52 Week High
- WSC $42.15
- KRYS $207.84
- Technical
- Relative Strength Index (RSI)
- WSC 38.71
- KRYS 55.22
- Support Level
- WSC $22.86
- KRYS $145.47
- Resistance Level
- WSC $25.08
- KRYS $152.57
- Average True Range (ATR)
- WSC 0.73
- KRYS 4.10
- MACD
- WSC 0.07
- KRYS 0.33
- Stochastic Oscillator
- WSC 36.64
- KRYS 74.26
About WSC WillScot Mobile Mini Holdings Corp.
WillScot Holdings Corp designs, delivers, and services onsite, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company includes modular office complexes, mobile offices, portable storage containers, and others.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.